Radius Health (RDUS) Earns Daily Media Impact Rating of 0.20
Media stories about Radius Health (NASDAQ:RDUS) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Radius Health earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.9171843614726 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Radius Health, Inc. (RDUS) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- Steven Cohen Boosts Stake in Radius Health (finance.yahoo.com)
- Radius Health reports 3Q loss (finance.yahoo.com)
- Radius Health (RDUS) Announces Commercial Leadership Changes (streetinsider.com)
Radius Health (NASDAQ:RDUS) opened at $27.87 on Friday. The company has a quick ratio of 12.79, a current ratio of 12.87 and a debt-to-equity ratio of 0.53. Radius Health has a 52-week low of $24.66 and a 52-week high of $55.30.
Several equities research analysts have recently commented on the company. ValuEngine upgraded Radius Health from a “strong sell” rating to a “sell” rating in a research note on Friday. Cantor Fitzgerald restated a “buy” rating and set a $58.00 price target on shares of Radius Health in a research note on Friday, November 3rd. Jefferies Group cut their price target on Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a research note on Friday, November 3rd. Goldman Sachs Group restated a “neutral” rating and set a $45.00 price target on shares of Radius Health in a research note on Friday, October 6th. Finally, Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $51.00.
In other Radius Health news, major shareholder Growth N. V. Biotech acquired 50,000 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was purchased at an average price of $36.75 per share, for a total transaction of $1,837,500.00. Following the completion of the transaction, the insider now owns 5,298,799 shares of the company’s stock, valued at approximately $194,730,863.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Brent Hatzis-Schoch acquired 1,778 shares of the business’s stock in a transaction on Friday, November 10th. The stock was acquired at an average price of $28.09 per share, with a total value of $49,944.02. Following the transaction, the vice president now directly owns 2,278 shares of the company’s stock, valued at approximately $63,989.02. The disclosure for this purchase can be found here. Insiders acquired 417,678 shares of company stock valued at $13,583,998 in the last quarter. 15.00% of the stock is currently owned by company insiders.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.